As World Obesity Day spotlights rising obesity rates, GLP-1s reshape treatment and coverage debates, with persistence, affordability and long-term value driving payer decisions. Most days, including World Obesity Day, the conversations around weight management have been much different than they were just a few years ago. Obesity rates remain high, but new data suggests injectable glucagon-like peptide-1 (GLP-1) drugs are beginning to influence both clinical practice and utilization trends across the healthcare system.
Many of the nation’s largest health plans trust FAIR Health to store, de-identify, aggregate and analyze their claims data. Our processes for handling data contributions meet the industry’s most exacting standards, as demonstrated by our HITRUST, SOC 2 and CMS QE certifications.
FAIR Health has earned the trust of many of the nation’s largest health plans, which rely on us to store, de-identify, aggregate and analyze their claims information.
Wed, June 3, 2026
Webinar on FAIR Health Atlas: A New Way of Visualizing Chronic Disease Data